To include your compound in the COVID-19 Resource Center, submit it here.
Bristol-Myers Squibb Co. (NYSE:BMY) will acquire IFM Therapeutics Inc. (Boston, Mass.), gaining two preclinical programs focused on stimulating the innate immune system to treat cancer.
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury